Related Experiment Video

Updated: Aug 17, 2026

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating
05:35

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Published on: June 23, 2018

Heparin-Coated Coronary Stents

van Der Giessen WJ1, van Beusekom HM, Larsson

  • 1Thoraxcenter, Erasmus University, Dijkigt dr. Molewatersplein 40, 3015 GD Rotterdam, The Netherlands.

Current Interventional Cardiology Reports
|November 30, 2000
PubMed

Insights

Heparin-coated stents show low thrombosis rates, even in acute coronary syndromes. While large trials are needed to confirm benefits over non-coated stents, they have advanced stent therapy in cardiology.

Area of Science:

  • Interventional Cardiology
  • Biomaterials Science

Background:

  • Early bare-metal stents had unfavorable outcomes before advanced imaging and antiplatelet therapies.
  • Heparin-coated (HC) stents were developed to improve safety and efficacy in coronary interventions.

Purpose of the Study:

  • To evaluate the incidence of stent thrombosis with HC stents.
  • To compare the efficacy of HC stents versus non-coated stents in challenging clinical scenarios.

Main Methods:

  • Review of pilot and randomized trials involving HC stents.
  • Preliminary comparison of available trial data.

Main Results:

  • Pilot and randomized trials demonstrate a low incidence of (sub)acute stent thrombosis with HC stents, even in acute coronary syndromes.
  • HC stents may be as effective as non-coated stents combined with abciximab therapy.
  • HC stents have facilitated wider adoption of stent therapy in interventional cardiology.

Conclusions:

  • Heparin-coated stents exhibit a low thrombosis rate, offering a safe option in complex cases.
  • While definitive clinical superiority over non-coated stents requires further large-scale trials, HC stents have significantly contributed to the advancement of coronary stenting.
  • The development of HC stents has played a crucial role in the increased utilization and acceptance of stent therapy for ischemic heart disease.

More Related Videos

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow09:41

Hemocompatibility Testing of Blood-Contacting Implants in a Flow Loop Model Mimicking Human Blood Flow

Published on: March 5, 2020

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Cardiac Catheterization I: Pre-Procedure Overview01:28

Cardiac Catheterization I: Pre-Procedure Overview

Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
Cardiac Catheterization IV: Nursing Management01:26

Cardiac Catheterization IV: Nursing Management

Nursing responsibilities before cardiac catheterization include:Assess for allergies and establish baseline health status.Before cardiac catheterization, assess the patient for allergies to contrast dye. Perform a comprehensive baseline assessment, including vital signs, heart and breath sounds, and a neurovascular assessment of the extremities, noting distal pulses, skin color, and temperature. Instruct the patient to fast for 8-12 hours before the procedure. Evaluate baseline laboratory...